inflamm
assist
defens
microbi
infect
heal
injuri
often
associ
tumor
growth
strict
regul
inflammatori
respons
essenti
normal
tissu
function
inappropri
inflammatori
respons
may
lead
perman
tissu
damag
chronic
inflamm
autoimmun
diseas
furthermor
progenitor
cell
retent
bone
marrow
leukocyt
home
lymphoid
organ
physiolog
patholog
process
strictli
regul
chemokin
identifi
crucial
player
regul
leukocyt
home
leukocyt
extravas
inflammatori
process
biolog
activ
chemokin
depend
interact
gpcr
ackr
addit
chemokin
avail
vivo
also
depend
interact
chemokin
specif
matrix
gag
regul
chemokin
activ
occur
multipl
level
includ
gene
duplic
classic
transcript
translat
regul
ligand
receptor
express
altern
splice
modif
chemokin
activ
crucial
initi
resolut
inflammatori
respons
respect
migrat
progenitor
matur
leukocyt
lymphoid
organ
lymphoid
organ
peripher
tissu
alter
chemokin
receptor
express
crucial
mechan
matur
differenti
lymphocyt
dendrit
cell
consequ
home
particular
organ
tumor
initi
stage
inflamm
enforc
posit
regulatori
mechan
via
enhanc
chemokin
product
synerg
chemokin
augment
local
leukocyt
influx
rapidli
instanc
synerg
cc
chemokin
leukocyt
recruit
enhanc
inflammatori
respons
chemokin
modif
frequent
exclus
observ
inflammatori
chemokin
modif
proteolyt
process
eg
mmp
aminopeptidas
dpp
glycosyl
detect
natur
chemokin
differ
consequ
biolog
activ
go
effect
decreas
increas
activ
alter
receptor
specif
chemokin
eg
proteolyt
cleavag
result
enhanc
biolog
activ
even
requir
truncat
becom
chemotact
activ
moreov
proteolyt
cleavag
differ
affect
bind
signal
capac
chemokin
eg
variou
cognat
receptor
furthermor
receptor
antagonist
gener
proteolyt
cleavag
instanc
result
proteolyt
process
devoid
chemotact
activ
act
monocyt
chemotaxi
antagonist
diminish
inflamm
glycosyl
describ
cc
chemokin
well
addit
truncat
glycosyl
citrullin
ie
deimin
arginin
citrullin
identifi
natur
chemokin
modif
citrullin
isol
cell
condit
medium
enzym
respons
convers
peptidylarginin
peptidylcitrullin
peptidylarginin
deiminas
play
import
role
autoimmun
diseas
rheumatoid
arthriti
multipl
sclerosi
whether
chemokin
citrullin
also
affect
diseas
outcom
diseas
progress
patient
need
investig
similar
endogen
regulatori
mechan
infiltr
human
bodi
modul
activ
chemokin
network
product
molecul
chemokin
chemokin
receptor
analog
enzym
may
serv
mechan
escap
effici
immun
respons
summari
process
often
chang
interact
chemokin
receptor
henc
influenc
biolog
activ
posit
neg
depend
substrat
proteas
involv
review
focus
current
knowledg
modif
serin
proteas
biolog
consequ
action
chemokin
understand
better
role
connect
physiolog
patholog
process
marker
dpp
iv
ec
belong
peptidas
famili
http
meropssangeracukcgibinfamsum
famili
prolyl
oligopeptidas
also
contain
fibroblast
activ
protein
dpp
iidpp
dpp
dpp
first
describ
enzymat
activ
hydrolyz
rat
liver
serin
type
peptidas
remov
dipeptid
end
peptid
chain
penultim
residu
prolin
alanin
certain
condit
amino
acid
may
accept
natur
substrat
includ
neuropeptid
peptid
hormon
vasoact
peptid
chemokin
growth
factor
cytokin
remark
mani
substrat
activ
gpcr
although
structur
characterist
quit
divers
best
studi
function
regul
incretin
hormon
control
glucos
metabol
hematopoiesi
immun
cancer
biolog
also
influenc
apart
catalyt
activ
interact
sever
protein
instanc
adenosin
deaminas
tyrosin
phosphatas
fibronectin
collagen
chemokin
receptor
hiv
protein
addit
indirectli
facilit
entri
cytopath
effect
hiv
strain
probabl
mediat
via
reduc
receptor
capac
major
entri
factor
middl
east
respiratori
syndrom
coronaviru
role
within
immun
system
combin
exopeptidas
activ
interact
differ
molecul
enabl
regul
hpchsc
home
engraft
growth
serv
costimulatori
molecul
influenc
cell
activ
modul
leukocyt
chemotaxi
mobil
rather
ubiquit
express
blood
cell
fibroblast
mesotheli
epitheli
endotheli
cell
detect
placenta
kidney
intestin
prostat
gall
bladder
pancrea
liver
furthermor
modul
express
malign
hematolog
solid
tumor
cell
report
may
help
cytolog
diagnosi
adhes
molecul
bind
extracellular
matrix
protein
collagen
fibronectin
might
promot
adhes
migrat
metastasi
tumor
cell
absenc
associ
tumor
develop
certain
cancer
eg
express
decreas
ovarian
carcinoma
melanoma
progress
wherea
presenc
also
correl
aggress
clinic
behavior
tumor
type
includ
cell
malign
multifunct
natur
explain
seemingli
contrast
effect
apart
express
solid
normal
demonstr
sever
leukocyt
eg
dendrit
cell
activ
b
cell
nk
cell
cell
human
progenitor
cell
character
origin
cell
subset
marker
present
rest
cell
systemat
lower
level
detect
compar
cell
express
membran
antigen
strongli
activ
therefor
suitabl
marker
activ
cell
express
high
level
constitut
subpopul
memori
cell
produc
respons
mitogen
alloantigen
stimul
uniqu
popul
cell
one
respond
recal
antigen
induc
synthesi
igg
b
cell
activ
cytotox
cell
furthermor
may
function
altern
pathway
cell
activ
express
hpc
may
affect
chemokin
activ
vide
infra
howev
growth
factor
substrat
may
also
provid
loop
activ
csf
addit
proteas
solubl
form
exist
enzymat
fulli
activ
occur
high
level
semin
fluid
lower
amount
detect
plasma
urin
cerebrospin
fluid
solubl
activ
act
biomark
sever
patholog
condit
instanc
level
enzymat
activ
plasma
independ
prognost
factor
surviv
colorect
cancer
patient
addit
plasma
activ
predictor
onset
insulin
resist
metabol
syndrom
appar
healthi
chines
recent
suggest
adipokin
potenti
link
obes
insulin
resist
metabol
syndrom
long
time
enzym
releas
cellular
surfac
remain
unknown
howev
et
al
recent
demonstr
sever
mmp
cleav
set
free
extracellular
catalyt
domain
involv
shed
adipocyt
releas
human
vascular
smooth
muscl
cell
conclud
substrat
highlight
review
name
chemokin
often
express
similar
condit
eg
inflamm
hematopoiesi
malign
transform
inde
larg
number
cell
detect
peripher
blood
andor
inflam
tissu
patient
multipl
sclerosi
grave
diseas
tuberculoid
leprosi
rheumatoid
arthriti
rheumatoid
arthriti
express
increas
cell
infiltr
synovi
caviti
togeth
enhanc
level
sever
chemokin
inflammatori
stimuli
express
also
induc
chemokin
transcript
instanc
differenti
adipocyt
increas
releas
express
chemokin
includ
substrat
fibroblast
alon
presenc
andor
induc
coexpress
substrat
chemokin
furthermor
mesotheli
cell
line
abdomin
caviti
express
basal
level
expressionact
factor
present
malign
ascit
contain
mani
inflammatori
constitut
chemokin
substrat
current
inhibitor
approv
us
food
drug
administr
european
medicin
agenc
sitagliptin
saxagliptin
linagliptin
alogliptin
vildagliptin
base
structur
inhibitor
broadli
divid
class
inhibitor
vildagliptin
nonpeptidomimet
linagliptin
sever
drug
test
advanc
clinic
trial
inhibitor
current
appli
inhibit
promin
studi
function
name
role
glucos
homeostasi
proteolyt
inactiv
insulinotrop
hormon
incretin
insulinotrop
polypeptid
gip
peptid
releas
respons
food
intestin
lumen
potenti
product
releas
insulin
glucos
clearanc
cleavag
complet
inactiv
incretin
follow
evid
anim
model
type
diabet
therapeut
benefit
inhibitor
stabil
incretin
vivo
inhibitor
analog
approv
therapeut
diabet
patient
prolong
incretin
effect
therapeut
improv
glucos
toler
addit
inhibitor
eg
sitagliptin
improv
pancreat
islet
cell
function
patient
type
diabet
prolong
activ
gipr
induc
prolifer
reduc
apoptosi
current
sitagliptin
also
consid
therapi
treat
patient
autoimmun
type
diabet
inhibit
properti
may
preserv
increas
mass
treatment
drug
incretin
famili
effici
known
oral
antidiabet
drug
safer
sulfonylurea
treatment
compar
incid
hypoglycem
event
safeti
profil
inhibitor
fact
good
seriou
advers
event
report
number
compar
placebo
group
contrast
inhibitor
analog
effect
bodi
weight
decreas
food
intak
contraind
patient
moder
sever
renal
failur
addit
diabet
patient
also
suffer
coronari
heart
diseas
claim
initi
treatment
sitagliptin
improv
heart
function
coronari
arteri
perfus
howev
recent
complet
studi
fail
demonstr
inhibitor
lower
incid
major
advers
cardiovascular
event
sever
year
use
individu
type
diabet
cardiovascular
diseas
fact
inhibitor
might
act
cardioprotect
surpris
larg
spectrum
peptid
includ
sever
cardioprotect
peptid
metabol
indic
inhibitor
multitarget
drug
multipl
effect
effect
inhibitor
also
evalu
patholog
consid
import
instanc
inhibitor
sitagliptin
protect
effect
rat
model
induc
colon
carcinogenesi
reduc
number
precancer
lesion
anim
analog
sitagliptin
treatment
shown
reduc
melanoma
growth
mice
result
delay
chemokin
process
vide
infra
latter
studi
explor
possibl
therapeut
intervent
block
chemokin
process
inde
chemokin
good
substrat
rapidli
cleav
discuss
cleav
first
aa
peptidesprotein
penultim
prolin
alanin
residu
sever
cytokin
chemokin
character
presenc
xp
motif
although
cytokin
reportedli
cleav
recent
hematopoiet
growth
factor
erythropoietin
identifi
sensit
truncat
howev
number
chemokin
discov
previous
first
substrat
immun
function
fig
differ
suscept
cleavag
cytokin
chemokin
probabl
partial
base
differ
size
protein
cytokin
gener
larger
protein
compar
chemokin
addit
chemokin
terminu
flexibl
structur
therefor
easili
fit
activ
site
proteas
includ
late
first
chemokin
describ
substrat
year
follow
recent
process
activ
discov
addit
chemokin
sensit
cleavag
contrast
data
publish
regard
suscept
cleavag
dissimilar
suscept
publish
might
result
differ
chemokin
concentr
use
incub
oligomer
higher
concentr
might
limit
cleavag
therefor
mask
potenti
cleavag
investig
requir
confirm
hypothesi
presenc
xp
xa
dipeptid
necessari
howev
suffici
truncat
chemokin
chemokin
character
motif
ie
prove
resist
cleavag
resist
mcp
result
presenc
pyroglutam
acid
terminu
result
convers
glutamin
residu
render
chemokin
fulli
activ
recombin
gln
instead
pyroglutam
acid
present
natur
inde
cleav
data
show
addit
penultim
prolin
surround
residu
access
terminu
import
substrat
recognit
although
chemokin
cleav
behind
residu
locat
rather
unstructur
flexibl
region
huge
kinet
differ
observ
comparison
chemokin
presenc
kcatkm
valu
reveal
clear
substrat
select
data
confirm
amino
acid
surround
scissil
bond
influenc
substrat
select
furthermor
dimer
chemokin
may
imped
access
region
may
explain
lower
kinet
describ
experiment
condit
may
form
aggreg
therefor
kinet
may
underestim
compar
kinet
natur
condit
hypothesi
also
support
fact
chemokin
isoform
miss
dipeptid
isol
natur
sourc
vide
infra
interestingli
cleavag
restrict
remov
gp
dipeptid
contrari
remov
first
residu
cleav
second
time
specif
peptid
bond
howev
cleavag
peptid
bond
occur
definit
much
slower
peptid
bond
result
accumul
degrad
cleavag
behind
penultim
gli
residu
highli
uncommon
probabl
strongli
depend
natur
surround
amino
acid
cleavag
chemokin
neg
regul
presenc
gag
bind
gag
import
format
chemokin
gradient
extracellular
matrix
present
chemokin
endothelium
describ
protect
process
protect
probabl
depend
express
level
structur
type
gag
express
might
locat
specif
find
howev
gener
process
inhibit
gag
bind
cleavag
may
turn
chemokin
suscept
cleavag
aminopeptidas
inde
prolin
residu
near
terminu
serv
structur
protect
peptid
bond
proteolyt
degrad
aminopeptidas
remov
prolin
residu
may
render
protein
suscept
aminopeptidas
thu
prone
degrad
inflammatori
respons
exampl
intact
resist
cleavag
aminopeptidas
result
presenc
prolin
residu
penultim
posit
upon
cleavag
remov
prolin
residu
chemokin
becom
effici
substrat
unpublish
result
fig
studi
chemokin
product
numer
cell
cultur
fibroblast
leukocyt
tumor
cell
line
etc
stimul
tlr
ligand
andor
cytokin
mimick
inflammatori
reaction
produc
chemokin
analyz
purif
biochem
character
ms
reveal
product
signific
amount
chemokin
isoform
might
result
cleavag
list
fig
exampl
given
list
meant
exhaust
purif
truncat
chemokin
isoform
condit
media
broad
array
cultur
cell
underscor
import
interact
chemokin
cleavag
chemokin
clearli
influenc
activ
chemokin
howev
rather
character
gener
consequ
effect
truncat
highli
divers
either
differ
activ
drastic
alter
receptor
recognit
specif
henc
biolog
activ
observ
fig
chemokin
cleavag
lead
reduc
chemokin
activ
occasion
gener
receptor
antagonist
proteolyt
cleavag
result
reduc
bind
affin
loss
signal
chemotact
properti
peripher
blood
lymphocyt
data
may
explain
peripher
blood
lymphocyt
less
effici
attract
peripher
blood
lymphocyt
analog
inhibit
cell
report
prolong
protein
kinas
b
signal
via
upon
stimul
parallel
also
lose
chemotact
effect
hpchsc
thu
capac
function
retent
signal
bone
marrow
moreov
truncat
block
respons
hpc
intact
accordingli
chemotaxi
hpc
enhanc
pretreat
hpc
inhibitor
use
mous
bone
marrow
cell
addit
remov
dipeptid
clearli
lower
affin
analog
truncat
result
reduc
chemotact
potenc
eosinophil
howev
bind
diminish
result
abl
desensit
partial
antagon
chemotaxi
truncat
isoform
gener
show
reduc
lymphocyt
chemotaxi
explain
reduc
bind
signal
contrast
monocyt
bind
chemotaxi
remain
unaffect
indic
possibl
involv
anoth
receptor
apart
process
biolog
inactiv
result
cleavag
observ
ligand
truncat
unabl
induc
chemotaxi
cell
concentr
higher
minim
effect
concentr
intact
counterpart
retain
weak
properti
partial
antagon
chemotaxi
induc
intact
counterpart
surprisingli
angiostat
activ
remain
unchang
process
nevertheless
upon
truncat
angiostat
activ
impair
well
cc
chemokin
constitut
express
varieti
tissu
cell
abundantli
present
plasma
depend
proteolyt
process
activ
process
plasmin
urokinas
plasminogen
activ
necessari
becom
agonist
specif
activ
compar
howev
cleavag
possibl
combin
gener
inact
variant
therefor
subtl
equilibrium
enzym
determin
fate
chemokin
effect
truncat
depend
receptor
involv
first
identifi
chemokin
studi
detail
activ
regard
signal
assay
chemotaxi
test
monocyt
eosinophil
even
act
antagonist
vitro
monocyt
chemotaxi
assay
contrast
lymphocyt
chemotact
activ
remain
unaffect
appar
contradictori
result
explain
loss
express
monocyt
potenc
even
moder
increas
interact
function
express
lymphocyt
thu
appear
modul
chemoattract
chang
receptor
select
also
observ
nonallel
variant
latter
differ
aa
among
residu
make
contrast
substrat
cleavag
enhanc
bind
signal
strongli
moder
accord
act
extrem
potent
monocyt
lymphocyt
chemoattract
truncat
opposit
effect
bind
signal
via
third
receptor
recogn
result
impair
bind
signal
eosinophil
undetect
express
migrat
respons
intact
truncat
eosinophil
show
high
express
case
donor
howev
reduc
signal
truncat
enhanc
respons
make
truncat
equal
stimul
eosinophil
chemotaxi
close
relat
chemokin
retain
activ
upon
cleavag
moreov
contrast
becom
activ
unlik
chemokin
substrat
biolog
activ
neutrophil
chemoattract
remain
unaffect
upon
cleavag
major
chemoattract
leukocyt
express
provid
loop
exampl
activ
lymphocyt
attract
ligand
express
use
specif
inhibitor
ludwig
et
al
demonstr
cleavag
cell
result
therefor
infiltr
cell
may
result
cleavag
chemokin
gener
inact
even
antagonist
variant
prevent
infiltr
activ
cell
consid
effect
cleavag
differ
leukocyt
subtyp
neutrophil
migrat
conclud
unaffect
presenc
inde
activ
neutrophil
chemoattract
cleav
ie
remain
unaffect
contrast
eosinophil
migrat
mediat
reduc
presenc
high
concentr
activ
chemokin
strongli
decreas
upon
cleavag
howev
case
eosinophil
show
high
express
reduc
signal
truncat
might
counteract
respons
truncat
effect
migrat
monocyt
lymphocyt
depend
monocytelymphocyt
subtyp
specif
chemokin
receptor
spectrum
express
chemokin
involv
migrat
lymphocyt
increas
wherea
migrat
cell
decreas
cell
express
might
exhibit
reduc
migrat
thu
chemokin
process
definit
impact
inflammatori
properti
chemokin
consequ
depend
chemokin
chemokin
receptor
involv
besid
bind
cognat
gpcr
chemokin
shown
interact
atyp
receptor
fine
tune
chemokin
avail
bind
intern
degrad
among
predominantli
express
lymphat
endotheli
cell
bind
inflammatori
cc
chemokin
interestingli
cleavag
influenc
bind
degrad
chemokin
isoform
ie
longer
bind
furthermor
process
potent
inflammatori
isoform
isoform
reduc
rate
degrad
although
bind
affin
remain
rather
unaffect
prolin
residu
posit
suggest
requir
rapid
chemokin
degrad
select
recogn
degrad
activ
chemokin
isoform
might
cooper
biolog
activ
chemokin
besid
involv
gener
adequ
immun
respons
upon
viral
bacteri
parasit
infect
chemokin
receptor
also
use
pathogen
hiv
infect
host
cell
success
major
breakthrough
hiv
research
made
chemokin
identifi
potent
inhibitor
infect
number
chemokin
receptor
shown
function
coreceptor
specif
hiv
strain
competit
bind
receptor
viral
glycoprotein
chemokin
inhibit
hiv
infect
main
coreceptor
hiv
strain
respect
cleavag
may
alter
receptor
specif
affin
multipl
chemokin
consequ
antivir
activ
process
chemokin
anticip
imped
infect
lymphocyt
bind
induc
endocytosi
viral
coreceptor
inhibitori
effect
infect
strain
strongli
reduc
upon
remov
dipeptid
accord
decreas
bind
affin
isoform
although
concentr
normal
serum
serum
aid
patient
technic
suffici
block
infect
seem
fail
prevent
infect
spread
vivo
seen
suscept
human
hiv
infect
natur
circul
blood
shown
rapidli
modifi
result
function
inact
molecul
might
explain
appar
contradictori
observ
major
coreceptor
strain
receptor
bind
multipl
cc
chemokin
includ
contrast
truncat
ligand
gain
receptor
affin
upon
truncat
becom
even
ligand
explain
enhanc
activ
interestingli
experi
cell
line
express
differ
level
membran
shown
invers
correl
valu
intact
express
cell
line
infect
data
suggest
intact
poor
antivir
activ
may
rapidli
convert
potent
antivir
isoform
upon
truncat
solubl
addit
intact
behav
rather
specif
agonist
howev
process
gener
ligand
retain
interact
activ
third
ligand
although
differ
aa
nonallel
variant
much
potent
inhibitor
infect
hiv
strain
import
protect
hiv
infect
illustr
associ
low
copi
number
gene
increas
risk
acquir
hiv
infect
progress
rapidli
aid
even
antivir
activ
yield
potent
inhibitor
infect
addit
sever
chemokin
receptor
eg
identifi
coreceptor
specif
hiv
strain
antivir
activ
chemokin
ligand
also
variabl
affect
process
truncat
chang
antivir
activ
strain
although
neither
signal
desensit
receptor
calcium
respons
isoform
partial
protect
pbmc
hiv
infect
bind
cognat
receptor
lost
upon
truncat
result
suggest
ligand
altern
receptor
involv
hiv
cell
entri
conclus
modif
chemokin
solubl
influenc
suscept
cell
hiv
infect
year
evid
actual
interact
chemokin
mere
base
local
includ
express
cell
membran
cell
involv
inflamm
plasma
primari
specif
cleavag
kinet
chemokin
purif
truncat
chemokin
isoform
condit
media
broad
array
cultur
cell
recent
vivo
studi
underscor
high
biolog
impact
relev
chemokin
interact
first
chemokin
cleavag
gener
isoform
lack
dipeptid
occur
vivo
inject
intraven
subcutan
analysi
plasma
min
postadministr
reveal
presenc
process
min
less
intraven
inject
convert
analog
fast
truncat
observ
upon
intraperiton
inject
mutant
isoform
reduc
affin
subsequ
analysi
present
serum
natur
occurr
chemokin
isoform
plasma
underscor
import
observ
cleavag
identifi
human
murin
rhesu
monkey
blood
plasma
furthermor
plasma
level
mice
rhesu
monkey
reduc
significantli
upon
treatment
inhibitor
analog
endogen
plasma
mice
intact
wherea
plasma
mice
contain
signific
amount
addit
level
endogen
intact
induc
intraven
inject
cpg
also
increas
significantli
mice
treat
sitagliptin
oral
activ
inhibitor
vide
supra
data
provid
vivo
evid
process
chemokin
evalu
biolog
activ
chemokin
mice
activ
inhibit
sitagliptin
absent
extend
knowledg
biolog
consequ
process
fig
mobil
eosinophil
blood
upon
intraven
administr
enhanc
significantli
rat
moreov
also
intraderm
inject
rat
result
increas
eosinophil
recruit
skin
analog
murin
abl
induc
signific
extravas
cell
upon
intraperiton
inject
mice
fed
sitagliptin
chow
mice
use
addit
data
show
administr
sitagliptin
via
drink
water
also
restor
activ
human
upon
intraperiton
inject
mice
unpublish
result
fig
modif
chemokin
activ
shown
influenc
diseas
progress
therapeut
efficaci
found
plasma
hcv
patient
correl
develop
chronic
hcv
infect
pegyl
treatment
failur
measur
concentr
plasma
chronic
hcv
patient
use
elisa
specif
discrimin
show
domin
form
circul
patient
truncat
antagonist
isoform
furthermor
concentr
antagonist
activ
significantli
higher
patient
respond
therapi
pegyl
cleavag
suggest
result
perturb
lymphocyt
traffick
liver
chronic
hcv
patient
later
patient
acut
viral
hcv
infect
show
patient
develop
chronic
infect
higher
plasma
concentr
truncat
compar
patient
spontan
resolv
infect
suggest
disturb
gradient
inhibit
develop
efficaci
innat
adapt
host
immun
respons
hcv
favor
evolut
viral
persist
likewis
follow
bcg
therapi
treatment
nonmuscl
invas
bladder
carcinoma
cleavag
might
limit
migrat
nk
cell
cell
therebi
counteract
antitumor
respons
elev
level
detect
urin
upon
treatment
differenti
measur
show
substanti
part
lack
dipeptid
hcv
patient
patient
bladder
carcinoma
treat
bcg
might
benefit
use
inhibitor
may
enhanc
efficaci
therapi
barreira
da
silva
colleagu
nice
show
delay
tumor
melanoma
colon
carcinoma
growth
mice
explain
enhanc
lymphocyt
infiltr
tumor
tissu
result
decreas
proteolyt
inactiv
moreov
combin
immunotherapi
intratumor
inject
cpg
adopt
cell
transfer
checkpoint
blockad
sitagliptin
treatment
clearli
enhanc
tumor
reject
respons
current
therapeut
approach
howev
benefici
role
syndrom
illustr
opposit
also
true
accumul
lymphoma
cell
skin
associ
impair
express
suggest
result
reduc
inactiv
abundantli
express
skin
acceler
home
skin
result
broad
spectrum
substrat
cleav
addit
function
costimulatori
adhes
molecul
vide
supra
antitumor
effect
inhibit
gener
inde
express
differ
tumor
type
associ
good
well
poor
prognos
depend
mechan
substrat
involv
underli
tumor
develop
progress
role
regul
hpc
traffick
ascrib
effect
axi
consid
respons
retain
hpc
bone
marrow
effici
bone
marrow
engraft
shown
involv
mobil
express
subpopul
human
cord
blood
cell
neg
regul
chemotaxi
cell
express
cell
enhanc
upon
treatment
result
decreas
chemotact
respons
inhibit
diprotin
inhibitor
absent
mice
treatment
mobil
hpc
mice
reduc
dramat
provid
evid
vivo
role
mobil
hpc
therefor
hypothes
express
cell
induc
cleavag
result
inactiv
loss
function
retent
signal
hpc
altern
proteas
neutrophil
elastas
cathepsin
g
also
suggest
influenc
hpc
mobil
degrad
might
cooper
constitut
hsc
mobil
seen
patient
chronic
myeloprolif
neoplasm
least
partial
ascrib
predomin
truncat
product
within
bone
marrow
plasma
compar
bone
marrow
plasma
healthi
control
contain
significantli
intact
research
show
inhibit
diprotin
loss
endogen
activ
donor
hpc
result
increas
home
effici
engraft
capabl
process
lethal
irradi
congen
mice
interestingli
coexpress
hschpc
block
activ
serv
endogen
regul
import
hsc
mainten
bone
marrow
hschpc
exhibit
decreas
potenti
migrat
home
resid
bone
marrow
addit
endogen
tfpi
import
mediat
coagul
cascad
ligand
enhanc
inhibit
activ
thu
far
tfpi
first
endogen
inhibitor
clinic
relev
describ
use
sitagliptin
effect
inhibit
hpc
engraft
transplant
patient
hematolog
malign
evalu
clinic
trial
pilot
studi
although
dose
schedul
sitagliptin
need
improv
pilot
studi
reveal
promis
target
improv
engraft
capac
allow
use
hpc
sourc
contain
limit
cell
number
cord
blood
effect
inhibit
hpc
mainten
traffick
believ
link
inhibit
inactiv
howev
hematopoiet
growth
factor
erythropoietin
recent
shown
neg
regul
truncat
well
furthermor
plenti
protein
involv
hematopoiesi
put
truncat
site
await
investig
might
also
involv
summari
modif
gener
regulatori
mechan
chemokin
activ
modif
affect
biolog
activ
mani
chemokin
howev
rather
character
common
effect
consequ
chemokin
truncat
highli
divers
either
differ
drastic
alter
chemotact
activ
observ
latter
mediat
chang
chemokin
receptor
recognit
specif
signal
besid
chemokin
receptor
chemokin
tend
bind
regul
mani
molecul
gag
microbi
protein
effect
cleavag
affin
chemokin
molecul
need
explor
furthermor
bind
molecul
might
affect
chemokin
suscept
cleavag
therefor
might
constitut
addit
dimens
regul
chemokin
activ
find
truncat
isoform
present
vivo
intravenousintraperiton
inject
certain
chemokin
mice
lead
rapid
truncat
underscor
import
cleavag
vivo
furthermor
potenti
regulatori
function
mani
physiolog
patholog
process
illustr
use
rodent
treat
inhibitor
knockout
rodent
leukocyt
hpc
tumor
cell
migrat
absenc
depend
chemokin
involv
process
although
vivo
data
limit
first
human
evid
support
import
role
regul
cell
traffick
publish
recent
increas
activ
concentr
associ
reduc
respons
therapi
hcv
patient
result
impair
gradient
henc
reduc
lymphocyt
traffick
addit
provision
data
show
treatment
sitagliptin
inhibitor
approv
treatment
patient
type
ii
diabet
result
increas
hpc
home
bone
marrow
upon
transplant
patient
hematolog
malign
therefor
control
activ
might
offer
potenti
therapeut
strategi
modul
chemokin
activ
therebi
enhanc
decreas
immun
respons
inflamm
tumorigenesi
particular
care
taken
chemokin
quantit
eg
elisa
detect
biolog
sampl
inform
vivo
process
function
provid
differenti
among
differ
modifi
chemokin
isoform
consid
measur
chemokin
determin
bioavail
use
therapeut
use
diagnost
molecul
elucid
diseas
mechan
howev
assay
allow
discrimin
among
differ
modifi
chemokin
form
almost
nonexist
therefor
develop
specif
assay
crucial
step
understand
role
individu
enzym
member
chemokin
network
patholog
mg
pp
ss
wrote
correct
manuscript
jvd
supervis
research
correct
manuscript
author
declar
conflict
interest
research
support
interunivers
attract
pole
programm
initi
belgian
scienc
polici
offic
iap
project
fund
scientif
research
flander
project
concert
research
action
region
govern
flander
hercul
foundat
flemish
govern
provid
fund
purchas
liquid
equip
contract
postdoctor
research
assist
author
thank
bo
vantilt
excel
technic
assist
